Literature DB >> 1445735

Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party.

J Cuzick1, D Allen, M Baum, J Barrett, G Clark, V Kakkar, E Melissari, C Moniz, J Moore, V Parsons.   

Abstract

A total of 153 breast cancer patients who participated in two trials of adjuvant tamoxifen and who had not recurred were recruited into a study of the long term effects of tamoxifen. There were 60 controls (no tamoxifen), 73 ex-users (mostly for 2 years) and 20 current users (median treatment duration 72 months) and the median follow-up time was 7 years. A wide ranging study of lipids, hormones, bone density and haemostasis was undertaken. When compared with controls, current users had lower cholesterol levels (especially low density cholesterol), and increased triglyceride levels. Thyroid hormones were higher and sex hormone binding globulin was almost doubled. Bone density was non-significantly higher, clotting times were slightly shorter and fibrinogen and antithrombin III levels were reduced. However few of these changes persisted in ex-users, suggesting that most of the biological effects of treatment are reversible on cessation of treatment. This is reassuring for potentially negative side-effects, but also indicates that potentially positive 'side-effects' such as cholesterol lowering only occur while on active treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445735     DOI: 10.1016/0959-8049(93)90568-z

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

Review 1.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

Review 2.  Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Authors:  F Khosrow-Khavar; K B Filion; S Al-Qurashi; N Torabi; N Bouganim; S Suissa; L Azoulay
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

3.  Tamoxifen alters hepatic cytochrome P450 enzyme expression and circulating growth hormone levels in intact male rats.

Authors:  Ludger M Ickenstein; Susan L Holsmer; Stelvio M Bandiera
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

4.  Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review.

Authors:  Alain Monnier
Journal:  Ther Clin Risk Manag       Date:  2009-09-15       Impact factor: 2.423

5.  The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients.

Authors:  D P Rose; J M Connolly; R T Chlebowski; I M Buzzard; E L Wynder
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

Review 6.  Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group.

Authors:  C C McDonald; F E Alexander; B W Whyte; A P Forrest; H J Stewart
Journal:  BMJ       Date:  1995-10-14

8.  Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats.

Authors:  Y P Dragan; S Fahey; K Street; J Vaughan; V C Jordan; H C Pitot
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  Investigation of female survival benefit in metastatic melanoma.

Authors:  B Richardson; A Price; M Wagner; V Williams; P Lorigan; S Browne; J G Miller; S Mac Neil
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.